KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(14 sites)

United States

UCSF Medical Center at Mission Bay ( Site 5044), San Francisco, California

Cleveland Clinic Taussig Cancer ( Site 5036), Cleveland, Ohio

Huntsman Cancer Institute ( Site 5041), Salt Lake City, Utah

Chile

FALP ( Site 5151), Santiago, Region M. de Santiago

France

CHU de Bordeaux Hop St ANDRE ( Site 5607), Bordeaux, Gironde